International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 62, Issue 9, 2003, Pages 817-824

  Braun, J ^a,b   Pham, T ^c   Sieper, J ^b,d   Davis, J ^e   Van Der Linden, Sj ^f   Dougados, M ^g   Van Der Heijde, D ^h  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HÔPITAL DE LA CONCEPTION   (France)

^d German Natl Research Cent for   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g University of Paris ^*  (France)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DECISION MAKING; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; HEALTH CARE SYSTEM; HUMAN; PRACTICE GUIDELINE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG MONITORING; HUMANS; PATIENT SELECTION; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038423033     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.9.817     Document Type: Article

References (48)

1. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
2. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
3. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
4. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
5. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
6. Boonen A, van Der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-Van Molken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
7. Ward MM. Quality of life in patients with ankylosis spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
8. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20(suppl 28):S16-22.
9. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
10. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
11. Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis. The Bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286-91.
12. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis. The Bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.
13. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis 2002;61 (suppl III):iii19-23.
14. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997;24:2225-9.
15. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951-4.
16. Anderson JJ, Baron G, Van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
17. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:737-51.
18. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 2002;4:307-21.
19. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
20. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
21. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
22. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
23. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of a 6 month follow-up open-label study. Rheumatology (Oxford) 2002;41:1280-5.
24. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-17.
25. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Treatment of patients with severe ankylosing spondylitis with infliximab - a one year follow up. Arthritis Rheum 2001;44:2936-37.
26. Kruithof E, van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNF-α monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
27. Braun J, Brandt J, Listing J, Zink A, Alten R, Burnmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum (in press).
28. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
29. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
30. Gorman J, Sack KE, Davis JC JR. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.
31. Brandt J, Kariauzov A, Listing J, et al. Six months results of a German double-blind placebo controlled, phase-III clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
32. Davis J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, et al. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized trial. Arthritis Rheum (in press).
33. D'Agostinho MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 2002;46:840-2.
34. Hadi A, Hickling P, Brown M, Al-Nahhas A. Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology (Oxford) 2002;41:114-16.
35. Braun J, Baraliakos X, Golder W, et al. Improvement of spinal inflammation in ankylosing spondylitis (AS) by infliximab therapy as assessed by magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system. Arthritis Rheum 2003;48:1126-36.
36. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20(suppl 28):S152-7.
37. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61 (suppl II):ii2-7.
38. National Institute for Clinical Excellence (NICE). Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. March 2002. www.nice.org.uk.
39. Pham T, van der Heijde D, Calin A, Khan MA, van der Linden Sj, Bellamy N, et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 2003;62:812-16.
40. The AGREE Collaboration. Appraisal and guidelines for research and evaluation (AGREE) instrument. September 2001. www.agreecollaboration.org.
41. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, et al. Canadian Rheumatology Association Consensus on the use of anti-TNF-α-directed therapies in the treatment of spondylarthritis. J Rheumatol 2003;30:1356-63.
42. Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993;22:319-34.
43. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
44. Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
45. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74-6.
46. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
47. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002 15;47:506-12.
48. Braun J van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002;16:573-604.